The Globe and Mail reports in its Thursday edition that over 300 drugs will expire patent protection in Canada over the next decade, potentially saving insurance plans $94-billion, says Swiss generics giant Sandoz Group. The Globe's Chris Hannay writes that Sandoz's Canadian branch released an analysis Wednesday quantifying the market size of upcoming off-patent drugs and identifying government and insurance bottlenecks that may restrict patient access. The speed of regulatory approvals has become a top concern for the generic drug industry in Canada. The backlog of generic submissions has doubled in the past year. Health Canada has a target of assessing submissions within 180 days, which was met only 72 per cent of the time in the 2025-26 fiscal year. The Sandoz report's modelling suggests that, without generic options, public and private payers would pay $183-billion on more than 300 drugs when they go off patent -- or $89-billion if cheaper off-patent drugs were promptly available when legal. Sandoz Canada's Michel Robidoux says, "This is a great opportunity to [cut] health care costs." The single biggest year for new generics becoming available was 2026, when Novo Nordisk's protection for Ozempic expired.